Cardiac Pharmacology: Difference between revisions

Jump to navigation Jump to search

Cardiac Pharmacology (view source)

Revision as of 19:23, 27 May 2013

280 bytes added ,  27 May 2013
no edit summary
No edit summary
No edit summary
Line 319: Line 319:
|-
|-
|+Cardiovascular Drugs
|+Cardiovascular Drugs
|-
|-
!Drug Category
!Drug Type
!Drug Type
!Examples (generic name)
!Examples (generic name)
Line 327: Line 326:
!Side Effects (Prevalence %)
!Side Effects (Prevalence %)
|-
|-
|colspan="6" bgcolor="#E6E6FA"|'''Anti-hypertensives'''
|colspan="5" bgcolor="#E6E6FA"|'''Drug Category: ''Anti-hypertensives'''''
|-
|-
|rowspan="2"|
|rowspan="2"|Diuretics
|rowspan="2"|Diuretics
|rowspan="2"|Furosemide
|rowspan="2"|Furosemide
|Oedema
|Oedema
|Furosemide: 20-40mg once daily
|Furosemide: 20-40mg once daily
|rowspan="2"|Mild gastro-intestinal disturbances, pancreatitis, hepatic encephalopathy, postural hypotension, temporary increase in serum-cholesterol and triglyceride concentration, hyperglycaemia, acute urinary retention, electrolyte disturbances, metabolic alkalosis, blood disorders, hyperuricaemia, visual disturbances, tinnitus and deafness, and hypersensitivity reactions (including rash, photosensitivity, and pruritus).<cite>Esc1</cite>
|rowspan="2" valign="top"|Mild gastro-intestinal disturbances, pancreatitis, hepatic encephalopathy, postural hypotension, temporary increase in serum-cholesterol and triglyceride concentration, hyperglycaemia, acute urinary retention, electrolyte disturbances, metabolic alkalosis, blood disorders, hyperuricaemia, visual disturbances, tinnitus and deafness, and hypersensitivity reactions (including rash, photosensitivity, and pruritus).<cite>Esc1</cite>
|-
|-
|Resistant Hypertension
|Resistant Hypertension
|Furosemide: 40-80mg once daily
|Furosemide: 40-80mg once daily
|-
|-
|
|rowspan="4"|ACE Inhibitors
|ACE Inhibitors
|rowspan="4"|Captopril, Monopril
|Captopril, monopril
|Hypertension
|Hypertension
|Captopril: 12.5mg twice daily
|Captopril: 12.5mg twice daily
|Hypotension (2.4%), renal impairment, persistent dry cough, angioedema, rash pancreatitis, upper respiratory-tract symptoms (2-10%), gastro-intestinal symptoms (1-2%), altered liver function tests, cholestatic jaundice, hepatitis, fulminant hepatic necrosis and failure, hyperkalaemia (2%), hypoglycaemia, blood disorders including thrombocytopenia, leucopenia, neutropenia, headache (3%), dizziness (2-12%), fatigue, malaise, taste disturbance, paraesthesia, bronchospasm, fever, serositis, vasculitis, myalgia (3%), arthralgia, positive antinuclear antibody, raised erythrocyte sedimentation rate, eosinophilia, leucocytosis, and photosensitivity.<cite>Esc2</cite><cite>Esc3</cite><cite>Esc4</cite>
|rowspan="4" valign="top"|Hypotension (2.4%), renal impairment, persistent dry cough, angioedema, rash pancreatitis, upper respiratory-tract symptoms (2-10%), gastro-intestinal symptoms (1-2%), altered liver function tests, cholestatic jaundice, hepatitis, fulminant hepatic necrosis and failure, hyperkalaemia (2%), hypoglycaemia, blood disorders including thrombocytopenia, leucopenia, neutropenia, headache (3%), dizziness (2-12%), fatigue, malaise, taste disturbance, paraesthesia, bronchospasm, fever, serositis, vasculitis, myalgia (3%), arthralgia, positive antinuclear antibody, raised erythrocyte sedimentation rate, eosinophilia, leucocytosis, and photosensitivity.<cite>Esc2</cite><cite>Esc3</cite><cite>Esc4</cite><cite>Esc5</cite><cite>Esc6</cite><cite>Esc7</cite>
|-
|-
|
|
|
|Heart Failure
|Heart Failure
|Captopril: 12.5mg 3 times daily<cite>Esc5</cite><cite>Esc6</cite><cite>Esc7</cite>
|Captopril: 12.5mg 3 times daily
|
|-
|-
|
|
|
|Prophylaxis Following MI
|Prophylaxis Following MI
|Captopril: 6.25mg once daily
|Captopril: 6.25mg once daily
|
|-
|-
|
|
|
|Diabetic nephropathy
|Diabetic nephropathy
|Captopril: 75-100mg once daily
|Captopril: 75-100mg once daily
|
|-
|-
|
|rowspan="3"|Angiotensin Receptor Blockers
|Angiotensin Receptor Blockers
|rowspan="3"|Losartan, Candesartan
|Losartan, candesartan
|Hypertension
|Hypertension
|Losartan: 50mg once daily
|Losartan: 50mg once daily
|Gastro-intestinal disturbances (<3%), dizziness (14%), angina, palpitation, oedema, dyspnoea, headache (14%), malaise, urticaria, pruritus, rash;<cite>Esc5</cite><cite>Esc8</cite><cite>Esc9</cite>
|rowspan="3" valign="top"|Gastro-intestinal disturbances (<3%), dizziness (14%), angina, palpitation, oedema, dyspnoea, headache (14%), malaise, urticaria, pruritus, rash;<cite>Esc5</cite><cite>Esc8</cite><cite>Esc9</cite><cite>Esc10</cite>
|-
|-
|
|
|
|Left ventricular hypertrophy
|Left ventricular hypertrophy
|Losartan: 12.5-150mg daily<cite>Esc10</cite>
|Losartan: 12.5-150mg daily
|
|-
|-
|
|
|
|Diabetic nephropathy
|Diabetic nephropathy
|Losartan: 50mg daily
|Losartan: 50mg daily
|
|-
|-
|
|rowspan="3"|Alpha Blockers
|Alpha Blockers
|rowspan="3"|Prazosin, Doxazosin
|Prazosin, Doxazosin
|Hypertension
|Hypertension
|Prazosin: 1-10mg 2-3 times daily
|Prazosin: 1-10mg 2-3 times daily
|Drowsiness, hypotension (notably postural hypotension) (10-70% initially), syncope (1%), asthenia, dizziness, depression, headache (8-18%), dry mouth, gastro-intestinal disturbances, oedema, blurred vision (<5%), intra-operative floppy iris syndrome, rhinitis (<4%), erectile disorders (including priapism), tachycardia and palpitations (7-14%), gastrointestinal side-symptoms (4-5%), hypersensitivity reactions including rash, pruritus and angioedema.
|rowspan="3" valign="top"|Drowsiness, hypotension (notably postural hypotension) (10-70% initially), syncope (1%), asthenia, dizziness, depression, headache (8-18%), dry mouth, gastro-intestinal disturbances, oedema, blurred vision (<5%), intra-operative floppy iris syndrome, rhinitis (<4%), erectile disorders (including priapism), tachycardia and palpitations (7-14%), gastrointestinal side-symptoms (4-5%), hypersensitivity reactions including rash, pruritus and angioedema.
|-
|-
|
|
|
|Congestive Heart Failure
|Congestive Heart Failure
|Prazosin: 4-20mg daily
|Prazosin: 4-20mg daily
|
|-
|-
|
|
|
|Raynaud’s Syndrome
|Raynaud’s Syndrome
|Prazosin: 1-2mg daily
|Prazosin: 1-2mg daily
|
|-
|-
|rowspan="4"|Beta Blockers
|
|rowspan="4"|Atenolol, Propranolol
|Beta Blockers
|Atenolol, Propranolol
|Hypertension
|Hypertension
|Atenolol: 25-50mg daily
|Atenolol: 25-50mg daily
|Gastro-intestinal disturbances (2-4%); bradycardia, heart failure, hypotension, conduction disorders, peripheral vasoconstriction, bronchospasm, dyspnoea; headache, fatigue, sleep disturbances (2-5%), paraesthesia, dizziness (2-5%), vertigo, psychoses; sexual dysfunction; purpura, thrombocytopenia; visual disturbances; exacerbation of psoriasis, alopecia; rarely rashes and dry eyes  
|rowspan="4" valign="top"|Gastro-intestinal disturbances (2-4%); bradycardia, heart failure, hypotension, conduction disorders, peripheral vasoconstriction, bronchospasm, dyspnoea; headache, fatigue, sleep disturbances (2-5%), paraesthesia, dizziness (2-5%), vertigo, psychoses; sexual dysfunction; purpura, thrombocytopenia; visual disturbances; exacerbation of psoriasis, alopecia; rarely rashes and dry eyes.<cite>Esc11</cite><cite>Esc12</cite>
|-
|-
|
|
|
|Angina
|Angina
|Atenolol: 100mg once/twice daily<cite>Esc11</cite><cite>Esc12</cite>
|Atenolol: 100mg once/twice daily
|
|-
|-
|
|
|
|Arrhythmias
|Arrhythmias
|Atenolol: 50-100mg daily<cite>Esc13</cite><cite>Esc14</cite><cite>Acc15</cite>
|Atenolol: 50-100mg daily
|
|-
|-
|
|
|
|Migraine
|Migraine
|Atenolol: 50-200mg daily
|Atenolol: 50-200mg daily
|
|-
|-
|
|rowspan="3"|Calcium Channel Blockers
|Calcium Channel Blockers
|rowspan="3"|Nifedipine, Verapamil, Diltiazem
|Nifedipine, Verapamil, Diltiazem
|Hypertension
|Hypertension
|Nifedipine: 20-30mg once daily
|Nifedipine: 20-30mg once daily
|Gastro-intestinal disturbance (2-11%); hypotension (1-5%), oedema (7-29%), vasodilatation, palpitation; headache (7-35%), dizziness (3-27%), lethargy (4-6%), asthenia (10-12%); less commonly tachycardia (<1-7%), syncope (<1%), chills, nasal congestion, dyspnoea (<3%), anxiety, sleep disturbance (<2%), vertigo (<3%), migraine, paraesthesia, tremor (1-8%), polyuria, dysuria, nocturia, erectile dysfunction (<2%), epistaxis, myalgia, joint swelling, visual disturbance (<2%), sweating (<2%), hypersensitivity reactions (<1%); rarely anorexia, gum hyperplasia, mood disturbances, hyperglycaemia, male infertility, purpura (<1%), and photosensitivity reactions (<1%); also reported dysphagia, intestinal obstruction, intestinal ulcer, bezoar formation, gynaecomastia, agranulocytosis, and anaphylaxis;<cite>Esc16</cite>
|rowspan="3" valign="top"|Gastro-intestinal disturbance (2-11%); hypotension (1-5%), oedema (7-29%), vasodilatation, palpitation; headache (7-35%), dizziness (3-27%), lethargy (4-6%), asthenia (10-12%); less commonly tachycardia (<1-7%), syncope (<1%), chills, nasal congestion, dyspnoea (<3%), anxiety, sleep disturbance (<2%), vertigo (<3%), migraine, paraesthesia, tremor (1-8%), polyuria, dysuria, nocturia, erectile dysfunction (<2%), epistaxis, myalgia, joint swelling, visual disturbance (<2%), sweating (<2%), hypersensitivity reactions (<1%); rarely anorexia, gum hyperplasia, mood disturbances, hyperglycaemia, male infertility, purpura (<1%), and photosensitivity reactions (<1%); also reported dysphagia, intestinal obstruction, intestinal ulcer, bezoar formation, gynaecomastia, agranulocytosis, and anaphylaxis;<cite>Esc16</cite><cite>Esc17</cite>
|-
|-
|
|
|
|Raynaud’s Syndrome
|Raynaud’s Syndrome
|Nifedipine: 5-20mg 3 times daily
|Nifedipine: 5-20mg 3 times daily
|
|-
|-
|
|
|
|Angina (prophylaxis)
|Angina (prophylaxis)
|Nifedipine: 5-20mg 3 times daily<cite>Esc17</cite>
|Nifedipine: 5-20mg 3 times daily
|
|-
|-
|colspan="6" bgcolor="#E6E6FA"|'''Anti-Arrhythmics'''
|colspan="5" bgcolor="#E6E6FA"|'''Drug Category: ''Anti-Arrhythmics'''''
|-
|-
|
|Class I (sodium channel blockers)
|Class I (sodium channel blockers)
|Flecainide, Lidocaine, Procainamide
|Flecainide, Lidocaine, Procainamide
Line 467: Line 411:
|Oedema, pro-arrhythmic effects (1-13%); dyspnoea; nervous-system side-effects including dizziness, asthenia, fatigue, fever; visual disturbances (13-28%); rarely pneumonitis, hallucinations, depression, confusion, amnesia, dyskinesia, convulsions, peripheral neuropathy; also reported gastro-intestinal disturbances (1-4%), anorexia, hepatic dysfunction, flushing, syncope, drowsiness, tremor, vertigo, headache, anxiety, insomnia, ataxia, paraesthesia, anaemia, leucopenia, thrombocytopenia, corneal deposits, tinnitus, increased antinuclear antibodies, hypersensitivity reactions (including rash, urticaria, and photosensitivity), increased sweating.<cite>Esc18</cite><cite>Acc19</cite>
|Oedema, pro-arrhythmic effects (1-13%); dyspnoea; nervous-system side-effects including dizziness, asthenia, fatigue, fever; visual disturbances (13-28%); rarely pneumonitis, hallucinations, depression, confusion, amnesia, dyskinesia, convulsions, peripheral neuropathy; also reported gastro-intestinal disturbances (1-4%), anorexia, hepatic dysfunction, flushing, syncope, drowsiness, tremor, vertigo, headache, anxiety, insomnia, ataxia, paraesthesia, anaemia, leucopenia, thrombocytopenia, corneal deposits, tinnitus, increased antinuclear antibodies, hypersensitivity reactions (including rash, urticaria, and photosensitivity), increased sweating.<cite>Esc18</cite><cite>Acc19</cite>
|-
|-
|
|Class II (Beta blockers)
|Class II (Beta blockers)
|(See above)
|(See above)
Line 474: Line 417:
|(See above)
|(See above)
|-
|-
|
|Class III (Potassium channel blockers)
|Class III (Potassium channel blockers)
|
|Amiodarone, Sotalol
*Amiodarone,
|Ventricular, Arrhythmias
*Sotalol
|
*Ventricular  
*Arrhythmias
|Amiodarone: 200mg 2-3 times daily
|Amiodarone: 200mg 2-3 times daily
|Gastro-intestinal disturbances (2-20%)), taste disturbances, hepatic disturbances (up to 50%); bradycardia; pulmonary toxicity (1-17%); tremor (9-59%), sleep disorders; hypothyroidism (5-10%), hyperthyroidism (5-10%); reversible corneal microdeposits (up to 98%); phototoxicity, persistent slate-grey skin discoloration (1-7%), injection-site reactions; less commonly onset or worsening of arrhythmia, conduction disturbances, peripheral neuropathy (1-105) and myopathy; very rarely sinus arrest, bronchospasm, ataxia (2-37%), benign intracranial hypertension, headache, vertigo, epididymo-orchitis, impotence, haemolytic or aplastic anaemia, thrombocytopenia, rash, hypersensitivity including photosensitivity (2-20%), anaphylaxis on rapid injection, hypotension (10-30%), respiratory distress syndrome, sweating, and hot flushes<cite>Esc20</cite><cite>Esc21</cite><cite>Acc22</cite>
|Gastro-intestinal disturbances (2-20%)), taste disturbances, hepatic disturbances (up to 50%); bradycardia; pulmonary toxicity (1-17%); tremor (9-59%), sleep disorders; hypothyroidism (5-10%), hyperthyroidism (5-10%); reversible corneal microdeposits (up to 98%); phototoxicity, persistent slate-grey skin discoloration (1-7%), injection-site reactions; less commonly onset or worsening of arrhythmia, conduction disturbances, peripheral neuropathy (1-105) and myopathy; very rarely sinus arrest, bronchospasm, ataxia (2-37%), benign intracranial hypertension, headache, vertigo, epididymo-orchitis, impotence, haemolytic or aplastic anaemia, thrombocytopenia, rash, hypersensitivity including photosensitivity (2-20%), anaphylaxis on rapid injection, hypotension (10-30%), respiratory distress syndrome, sweating, and hot flushes<cite>Esc20</cite><cite>Esc21</cite><cite>Acc22</cite>
|-
|-
|
|Class IV (Calcium channel blockers)
|Class IV (Calcium channel blockers)
|(See above)
|(See above)
Line 492: Line 429:
|(See above)
|(See above)
|-
|-
|
|rowspan="2"|
|
|rowspan="2"|Digoxin
|Digoxin
|Supra-ventricular Arrhythmias
|Supra-ventricular Arrhythmias
|
|Acute: 0.75-1.5mg over 24 hours; Maintenance: 125-150µg daily
*Acute: 0.75-1.5mg over 24 hours
|rowspan="3" valign="top"|Gastro-intestinal disturbances (vomiting, diarrhoea, anorexia, abdominal pain) (25%); arrhythmias (up to 50%), AV conduction disturbances (50%); nervous system disturbances (dizziness, apathy, confusion, headache, fatigue, weakness) (25%); blurred or yellow vision; rash, eosinophilia, depression, anorexia, intestinal ischaemia and necrosis, psychosis, gynaecomastia on long-term use, and thrombocytopenia.<cite>Acc23</cite><cite>Esc24</cite><cite>Esc25</cite>
*Maintenance: 125-150µg daily
|Gastro-intestinal disturbances (vomiting, diarrhoea, anorexia, abdominal pain) (25%); arrhythmias (up to 50%), AV conduction disturbances (50%); nervous system disturbances (dizziness, apathy, confusion, headache, fatigue, weakness) (25%); blurred or yellow vision; rash, eosinophilia, depression, anorexia, intestinal ischaemia and necrosis, psychosis, gynaecomastia on long-term use, and thrombocytopenia.<cite>Acc23</cite>
|-
|-
|
|
|
|Heart Failure
|Heart Failure
|62.5-125 µg daily<cite>Esc24</cite><cite>Esc25</cite>
|62.5-125 µg daily
|
|-
|-
|colspan="6" bgcolor="#E6E6FA"|'''Anti-platelet Drugs'''
|colspan="5" bgcolor="#E6E6FA"|'''Drug Category: ''Anti-platelet Drugs'''''
|-
|-
|
|rowspan="7"|
|
|rowspan="2"|Aspirin
|Aspirin
|Prevention of thrombotic cerebro- or cardio-vascular disease
|Prevention of thrombotic cerebro- or cardio-vascular disease
|75mg once/day
|75mg once/day
|Bronchospasm (10-30% in asthmatics); gastro-intestinal irritation (up to 83%), gastro-intestinal haemorrhage (occasionally major), also other haemorrhage (e.g. intracranial (0.5%), subconjunctival), chest pain (8.3%), oedema (4.5%), hypertension (4.3%).<cite>Esc26</cite><cite>Esc27</cite><cite>Esc28</cite><cite>Esc29</cite>
|rowspan="2" valign="top"|Bronchospasm (10-30% in asthmatics); gastro-intestinal irritation (up to 83%), gastro-intestinal haemorrhage (occasionally major), also other haemorrhage (e.g. intracranial (0.5%), subconjunctival), chest pain (8.3%), oedema (4.5%), hypertension (4.3%).<cite>Esc26</cite><cite>Esc27</cite><cite>Esc28</cite><cite>Esc29</cite>
|-
|-
|
|
|
|Pain / pyrexia
|Pain / pyrexia
|300-600mg every 4-6 hours as necessary
|300-600mg every 4-6 hours as necessary
|
|-
|-
|
|rowspan="3"|Clopidogrel
|
|Clopidogrel
|Prevention of thrombotic events (esp. when warfarin not tolerated)
|Prevention of thrombotic events (esp. when warfarin not tolerated)
|75mg once/day
|75mg once/day
|Dyspepsia (5.2%), abdominal pain (5.6%), diarrhoea (4.5%); bleeding disorders including gastro-intestinal (2.0%) and intracranial (0.4%), nausea (3.4%), vomiting, gastritis, flatulence, constipation, gastric and duodenal ulcers, headache (7.6%), epistaxis (2.9%), dizziness (6.2%), paraesthesia, leucopenia, decreased platelets (very rarely severe thrombocytopenia), eosinophilia, rash (4.2%), pruritus (3.3%), vertigo, colitis, pancreatitis, hepatitis (<1%), acute liver failure, hypertension (4.3%), chest pain (8.3%), oedema (4.1%), vasculitis, confusion, hallucinations, taste disturbance, cough (3.9%), fatigue (4.8%) stomatitis, bronchospasm, interstitial pneumonitis, pyrexia (2.2%), blood disorders including thrombocytopenic purpura (5.3%), agranulocytosis, neutropenia (0.04%) and pancytopenia and hypersensitivity-like reactions (<0.1%)including fever, glomerulonephritis, arthralgia, Stevens-Johnson syndrome, toxic epidermal necrolysis, lichen planus.<cite>Esc30</cite><cite>Esc31</cite><cite>Esc32</cite>
|rowspan="3" valign="top"|Dyspepsia (5.2%), abdominal pain (5.6%), diarrhoea (4.5%); bleeding disorders including gastro-intestinal (2.0%) and intracranial (0.4%), nausea (3.4%), vomiting, gastritis, flatulence, constipation, gastric and duodenal ulcers, headache (7.6%), epistaxis (2.9%), dizziness (6.2%), paraesthesia, leucopenia, decreased platelets (very rarely severe thrombocytopenia), eosinophilia, rash (4.2%), pruritus (3.3%), vertigo, colitis, pancreatitis, hepatitis (<1%), acute liver failure, hypertension (4.3%), chest pain (8.3%), oedema (4.1%), vasculitis, confusion, hallucinations, taste disturbance, cough (3.9%), fatigue (4.8%) stomatitis, bronchospasm, interstitial pneumonitis, pyrexia (2.2%), blood disorders including thrombocytopenic purpura (5.3%), agranulocytosis, neutropenia (0.04%) and pancytopenia and hypersensitivity-like reactions (<0.1%)including fever, glomerulonephritis, arthralgia, Stevens-Johnson syndrome, toxic epidermal necrolysis, lichen planus.<cite>Esc30</cite><cite>Esc31</cite><cite>Esc32</cite><cite>Esc33</cite><cite>Esc34</cite>
|-
|-
|
|
|
|Acute myocardial infarction
|Acute myocardial infarction
|300mg daily initially then 75mg once/day<cite>Esc33</cite>
|300mg daily initially then 75mg once/day
|
|-
|-
|
|
|
|Acute coronary syndrome
|Acute coronary syndrome
|300mg daily initially then 75mg once/day<cite>Esc34</cite>
|300mg daily initially then 75mg once/day
|
|-
|-
|
|
|Prasugrel
|Prasugrel
|Prevention of thrombotic events.
|Prevention of thrombotic events.
Line 552: Line 465:
|Haemorrhage (11.3%) (including gastro-intestinal (1.5%) and intracranial), haematoma, haematuria, hypertension (7.5%), hypotension (3.9%), headache (5.5%), back pain (5.0%), dyspnoea (4.9%), nausea (4.6%), dizziness (4.1%), cough (3.9%), fatigue (3.7%), chest pain (3.1%), arrhythmias including atrial fibrillation (2.9%) and bradycardia (2.9%), rash (2.8%), pyrexia (2.7%), oedema (2.7%), diarrhoea (2.3%), hypercholesterolaemia/hyperlipidaemia (7.5%), anaemia, rash,hypersensitivity reactions including angioedema (0.06%), thrombocytopenia (0.06%), thrombotic thrombocytopenic purpura.<cite>Esc35</cite><cite>Esc36</cite>
|Haemorrhage (11.3%) (including gastro-intestinal (1.5%) and intracranial), haematoma, haematuria, hypertension (7.5%), hypotension (3.9%), headache (5.5%), back pain (5.0%), dyspnoea (4.9%), nausea (4.6%), dizziness (4.1%), cough (3.9%), fatigue (3.7%), chest pain (3.1%), arrhythmias including atrial fibrillation (2.9%) and bradycardia (2.9%), rash (2.8%), pyrexia (2.7%), oedema (2.7%), diarrhoea (2.3%), hypercholesterolaemia/hyperlipidaemia (7.5%), anaemia, rash,hypersensitivity reactions including angioedema (0.06%), thrombocytopenia (0.06%), thrombotic thrombocytopenic purpura.<cite>Esc35</cite><cite>Esc36</cite>
|-
|-
|
|
|Ticragelor
|Ticragelor
|Prevention of thrombotic events.
|Prevention of thrombotic events.
Line 559: Line 470:
|Dyspnoea (13.8%), haemorrhage, bruising; nausea (4.3%), vomiting, diarrhoea (3.7%), hypertension (3.8%), hypotension (3.2%), back pain (3.6%), abdominal pain, dyspepsia, gastritis, dizziness (4.5%), chest pain (3.7%), headache (6.5%), cough (4.9%), rash, pruritus, fatigue (3.2%),  constipation, arrhythmias including atrial fibrillation (4.2%), paraesthesia, confusion, hyperuricaemia, raised serum creatinine (7.4%), vertigo.<cite>Esc37</cite><cite>Esc38</cite>
|Dyspnoea (13.8%), haemorrhage, bruising; nausea (4.3%), vomiting, diarrhoea (3.7%), hypertension (3.8%), hypotension (3.2%), back pain (3.6%), abdominal pain, dyspepsia, gastritis, dizziness (4.5%), chest pain (3.7%), headache (6.5%), cough (4.9%), rash, pruritus, fatigue (3.2%),  constipation, arrhythmias including atrial fibrillation (4.2%), paraesthesia, confusion, hyperuricaemia, raised serum creatinine (7.4%), vertigo.<cite>Esc37</cite><cite>Esc38</cite>
|-
|-
|colspan="6" bgcolor="#E6E6FA"|'''Vitamin K Antagonists'''
|colspan="5" bgcolor="#E6E6FA"|'''Drug Category: ''Vitamin K Antagonists'''''
|-
|-
|
|
|
|Warfarin
|Warfarin
|Prevention of thrombotic/ embolic events (esp. after prosthetic valve insertion)
|Prevention of thrombotic/ embolic events (esp. after prosthetic valve insertion)
|5-10mg initially then tailored to individual (usually 3-9mg once daily at the same time)
|5-10mg initially then tailored to individual (usually 3-9mg once daily at the same time)
|Haemorrhage, nausea, vomiting, diarrhoea, jaundice, hepatic dysfunction, pancreatitis, pyrexia, alopecia, purpura, rash, ‘purple toes’, skin necrosis (increased risk in patients with protein C or protein S deficiency)
|valign="top"|Haemorrhage, nausea, vomiting, diarrhoea, jaundice, hepatic dysfunction, pancreatitis, pyrexia, alopecia, purpura, rash, ‘purple toes’, skin necrosis (increased risk in patients with protein C or protein S deficiency)
|-
|-
|
|
|
|Acenocoumarol
|Acenocoumarol
|Prevention of thrombotic/ embolic events (esp. after prosthetic valve insertion)
|Prevention of thrombotic/ embolic events (esp. after prosthetic valve insertion)
|4mg initially, followed by 1-8mg daily
|4mg initially, followed by 1-8mg daily
|Haemorrhage, nausea, vomiting, diarrhoea, jaundice, hepatic dysfunction, pancreatitis, pyrexia, alopecia, purpura, rash, ‘purple toes’, skin necrosis (increased risk in patients with protein C or protein S deficiency)
|valign="top"|Haemorrhage, nausea, vomiting, diarrhoea, jaundice, hepatic dysfunction, pancreatitis, pyrexia, alopecia, purpura, rash, ‘purple toes’, skin necrosis (increased risk in patients with protein C or protein S deficiency)
|-
|-
|colspan="6" bgcolor="#E6E6FA"|'''Lipid-Lowering Drugs'''
|colspan="5" bgcolor="#E6E6FA"|'''Drug Category: ''Lipid-Lowering Drugs'''''
|-
|-
|
|rowspan="3"|Statins
|Statins
|rowspan="3"|Simvastatin, Atorvastatin
|Simvastatin, Atorvastatin
|Primary hyper-cholesterolaemia, combined hyperlipidaemia
|Primary hyper-cholesterolaemia, combined hyperlipidaemia
|Simvastatin: 10-20mg once daily
|Simvastatin: 10-20mg once daily
|Oedema (2.7%), abdominal pain (5.9%), nausea (5.4%), atrial fibrillation (5.7%), constipation (2.2%), gastritis (4.9%), diabetes mellitus (4.2%), myalgia (3.7%), headache (2.5%), insomnia (4.0%), vertigo (4.5%), bronchitis (6.6%), sinusitis (2.3%), eczema (4.5%), urinary tract infection (3.2%)<cite>Esc39</cite><cite>Esc40</cite>
|rowspan="3" valign="top"|Oedema (2.7%), abdominal pain (5.9%), nausea (5.4%), atrial fibrillation (5.7%), constipation (2.2%), gastritis (4.9%), diabetes mellitus (4.2%), myalgia (3.7%), headache (2.5%), insomnia (4.0%), vertigo (4.5%), bronchitis (6.6%), sinusitis (2.3%), eczema (4.5%), urinary tract infection (3.2%)<cite>Esc39</cite><cite>Esc40</cite><cite>Esc41</cite><cite>Esc42</cite>
|-
|-
|
|
|
|Familial hyper-cholesterolaemia
|Familial hyper-cholesterolaemia
|Simvastatin: 40mg once daily<cite>Esc41</cite>
|Simvastatin: 40mg once daily
|
|-
|-
|
|
|
|Prevention of cardiovascular events
|Prevention of cardiovascular events
|20-40mg once daily<cite>Esc42</cite>
|20-40mg once daily
|
|-
|-
|rowspan="2"|Fibrates
|
|Fibrates
|Gemfibrozil
|Gemfibrozil
|Hyperlipidaemias of types IIa, IIb, III, IV and V
|Hyperlipidaemias of types IIa, IIb, III, IV and V
Line 605: Line 504:
|Gastro-intestinal disturbances including dyspepsia (19.6%), nausea (4%), abdominal pain (9.8%), diarrhoea (7.2%), vomiting (1.2%); headache (1.2%), fatigue (3.8%), vertigo (1.5%), eczema, rash (1.7%), atrial fibrillation (0.7%), pancreatitis, appendicitis, disturbances in liver function including hepatitis and cholestatic jaundice, dizziness, paraesthesia, sexual dysfunction, thrombocytopenia, anaemia, leucopenia, eosinophilia, bone-marrow suppression, myalgia, myopathy, myasthenia, myositis accompanied by increase in creatine kinase, blurred vision, exfoliative dermatitis, alopecia, and photosensitivity<cite>Esc43</cite>
|Gastro-intestinal disturbances including dyspepsia (19.6%), nausea (4%), abdominal pain (9.8%), diarrhoea (7.2%), vomiting (1.2%); headache (1.2%), fatigue (3.8%), vertigo (1.5%), eczema, rash (1.7%), atrial fibrillation (0.7%), pancreatitis, appendicitis, disturbances in liver function including hepatitis and cholestatic jaundice, dizziness, paraesthesia, sexual dysfunction, thrombocytopenia, anaemia, leucopenia, eosinophilia, bone-marrow suppression, myalgia, myopathy, myasthenia, myositis accompanied by increase in creatine kinase, blurred vision, exfoliative dermatitis, alopecia, and photosensitivity<cite>Esc43</cite>
|-
|-
|
|
|Ezetimibe
|Ezetimibe
|Primary and familial hyper-cholesterolaemia
|Primary and familial hyper-cholesterolaemia
NiloferT
467

edits

Retrieved from "https://www.textbookofcardiology.org/wiki/Special:MobileDiff/2418"

Navigation menu